secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2025-07-08T23:59:59+00:00
Accession:  0000929638-25-002520
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene appoints Astley-Sparke, Grossman, Heffernan to board; promotes three executives
--------------------------------------------------------------------------------

- Philip Astley-Sparke, William Grossman, Michael Heffernan appointed to Board effective July 8, 2025; Jasper Bos resigned.
- Matthew Boyd promoted to Chief Regulatory Officer; Jill Buck to Chief Development Officer; Katherine Chan to Executive Director, Urology Clinical Lead.
- New board members have experience in gene therapy, oncology, and product launches; company advancing detalimogene toward planned commercialization.
- Board increased from seven to nine members after appointments; no disagreements cited for Bos resignation.
- Independent director compensation plan applies; indemnification agreements entered.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000092963825002520/0000929638-25-002520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000092963825002520/a8k.htm
  HTML page:      https://secwatch.observer/filing/0000929638-25-002520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer